Cardiovascular Institute Gift FAQ

This list of Frequently Asked Questions provides information about the recent gift made to OHSU from Nike co-founder and Chairman Phil Knight and his wife Penny to advance OHSU's world-class programs in cardiovascular medicine and research. Media inquiries may be directed to OHSU's office of Strategic Communications, at 503 494-8231.

What will the gift fund?

The gift will fund a new cardiovascular institute at OHSU that will bring new prevention, diagnostic and treatment strategies out of the laboratory and into the clinic as quickly as possible. OHSU will accomplish this goal through many means, including cutting-edge lab research, clinical trials that give heart patients access to the latest heart disease interventions, patient care, professional training and community outreach.

We are in the early stages of the planning process and will have more specific information about the institute’s strategic focus in the months ahead.

Is this the biggest gift in OHSU's history?

The gift is the largest in OHSU’s history and is thought to be the largest private contribution ever made by living donors to benefit a single Oregon organization.

Will the gift fund patient care or research?

Both. The purpose of the gift is to accelerate lifesaving research in the lab and propel it into clinics to treat and prevent cardiovascular disease.

Will OHSU build a new facility to house the institute?

The initial phase of this gift will be focused on programmatic and faculty support. The institute’s future plans may include a facility, but it is too early to say.

How will patients benefit?

Patients will benefit in many ways. This transformational gift will allow us to expand OHSU’s clinical and research expertise through the recruitment of additional experts in cardiovascular medicine and research. This will directly impact patient care. The expansion will also increase the availability of clinical trials for OHSU’s cardiovascular patients. Finally, the gift will accelerate and expand OHSU’s cardiovascular research so that we can more rapidly transition new discoveries in the lab into treatments in the clinic.